Long-term stabilization of vein graft wall architecture and prolonged resistance to experimental atherosclerosis after E2F decoy oligonucleotide gene therapy

This publication has 22 references indexed in Scilit:

• Pressure-mediated oligonucleotide transfection of rat and human cardiovascular tissues
  Proceedings of the National Academy of Sciences, 1999
• Inhibition of intimal hyperplasia after vein grafting by in vivo transfer of human senescent cell-derived inhibitor-1 gene
  Gene Therapy, 1998
• Antisense oligonucleotide to proto-oncogene c-myb inhibits the formation of intimal hyperplasia in experimental vein grafts
  Journal of Vascular Surgery, 1997
• Cellular Targets for Activation by the E2F1 Transcription Factor Include DNA Synthesis- and G₁/S-Regulatory Genes
  Molecular and Cellular Biology, 1995
• A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo.
  Proceedings of the National Academy of Sciences, 1995
• Genetic engineering of vein grafts resistant to atherosclerosis.
  Proceedings of the National Academy of Sciences, 1995
• The retinoblastoma protein and cell cycle control
  Cell, 1995
• Prevention of stenosis after vascular reconstruction: Pharmacologic control of intimal hyperplasia—A review
  Journal of Vascular Surgery, 1991
• The E2F transcription factor is a cellular target for the RB protein
  Cell, 1991
• The Relation of Risk Factors to the Development of Atherosclerosis in Saphenous-Vein Bypass Grafts and the Progression of Disease in the Native Circulation
  New England Journal of Medicine, 1984